Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
DOI10.1155/2012/567819zbMATH Open1263.62132OpenAlexW2020386060WikidataQ58910973 ScholiaQ58910973MaRDI QIDQ454783FDOQ454783
Galen Cook-Wiens, Mourad Tighiouart, André Rogatko
Publication date: 10 October 2012
Published in: Journal of Probability and Statistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1155/2012/567819
Recommendations
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
- Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
- Dose-finding with two agents in phase I oncology trials
- Designs foe phase i cancer clinical trials with differentiation of graded toxicity
- MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Title not available (Why is that?)
- Continual Reassessment Method for Ordered Groups
- Dose finding in drug development.
- TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
- Bayesian Optimal Designs for Phase I Clinical Trials
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Statistical Methods for Dose‐Finding Experiments
- A Curve‐Free Method for Phase I Clinical Trials
- Bayesian Nonparametric Inference on the Dose Level with Specified Response Rate
Cited In (2)
This page was built for publication: Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q454783)
